Brief: Reata Pharmaceuticals Inc Reports Q1 2023 Financial Results, Provides Update On Operational Progress And Clinical Development Programs
10/05/2023 13:41
May 10 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2023
FINANCIAL RESULTS AND PROVIDES AN UPDATE ON OPERATIONAL PROGRESS
AND CLINICAL DEVELOPMENT PROGRAMS
* ANNOUNCED $275 MILLION DEBT FACILITY AND EXTENDED CASH
GUIDANCE
THROUGH END OF 2026
* REATA PHARMACEUTICALS - ON MARCH 31, 2023, HAD CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES OF $321.0 MILLION
* QTRLY NET LOSS PER SHARE $3.14
* QTRLY NON-GAAP NET LOSS PER SHARE $1.81
* Q1 EARNINGS PER SHARE VIEW $-2.42, REVENUE VIEW $158250.00
--
REFINITIV IBES DATA
Source text for Eikon: ID:nBw7XFL9Pa
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer